Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

NCT02668666

Last updated date
Study Location
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Subjects must meet all of the following applicable inclusion criteria to participate in this study:

- Male or female ≥ 18 years of age at time of consent. NOTE: Both pre- and post-menopausal women are eligible. Pre-menopausal status is defined as either:

- Last menstrual period within the last 12 months.

- In case of therapy-induced amenorrhea, plasma estradiol and /or FSH is in the premenopausal range per local normal range.

- Locally advanced, locoregionally recurrent, or metastatic disease, not amenable to curative therapy. NOTE: Although not required as a protocol procedure, a patient with a new metastatic lesion should be considered for biopsy whenever possible to reassess ER/PR/HER2 status if clinically indicated. If a biopsy is prospectively done as part of standard of care, the study would like to store samples for correlative research.

- Histologically and/or cytologically confirmed diagnosis of ER positive and/or PR positive (ER >1%, PR >1%), HER2 negative breast cancer. NOTE: Subject has HER2-negative breast cancer (based on most recently analyzed biopsy) is defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (e.g. FISH, CISH, SISH, DISH, etc.) test is required by local laboratory testing.

- Metastatic disease evaluable on imaging studies. Subjects may have measurable disease as per RECIST 1.1 or bone-only disease. NOTE: Bone-only subjects are eligible if their disease can be documented/ evaluated by bone scans, CT or MRI. Their disease will be assessed using MDA criteria. NOTE: Previously irradiated lesions are eligible as a target lesion only if there is documented progression of the lesion after irradiation.

- No prior systemic anti-cancer therapy for advanced HR+ disease. NOTE: Subjects receiving adjuvant treatment with aromatase inhibitors at time of recurrence are allowed to participate. There is no AI washout period required.

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

- Provided written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization for release of personal health information, approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC). NOTE: HIPAA authorization may be included in the informed consent or obtained separately.

- Women of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within 72 hours of study registration from women of childbearing potential. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.

- Women of childbearing potential (WOCP) must be willing to use two effective methods of birth control such as use of a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence for the course of the study until 120 days after the last dose of study drug. The use of hormonal contraceptives is discouraged. NOTE: Women are considered to be of childbearing potential unless they are postmenopausal for at least 12 consecutive months or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

- Male subjects capable of fathering a child must agree to use adequate contraception or total abstinence for the course of the study until 120 days after the last dose of the study drug.

NOTE: Male subjects will be considered as capable of fathering a child unless they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition).

- Co-enrollment in an imaging biomarker study or other non-therapeutic study is allowed.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Subjects meeting any of the criteria below may not participate in the study:


- Prior treatment with any CDK 4/6 inhibitor.


- Confirmed diagnosis of HER2 positive disease.


- Known uncontrolled or symptomatic CNS metastases. Subjects with known brain metastasis
will only be eligible after their tumors have been treated with definitive resection
and /or radiotherapy and they are neurologically stable for at least 1 month off
steroids.


- Advanced, symptomatic, visceral spread with a life expectancy less than 4 months.


- Prior (neo)adjuvant treatment with tamoxifen within the 12 months before study entry.


- Prior history of blood clots, pulmonary embolism or deep vein thrombosis.


- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled
nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).


- Concurrent malignancy or malignancy within 3 years of randomization, with the
exception of adequately treated basal cell carcinoma, squamous cell skin carcinoma,
non-melanomatous skin cancer or curatively resected cervical cancer.


- Any other concurrent severe and/or uncontrolled medical condition that would, in the
investigator's judgment, contraindicate subject participation in the clinical study.


- Currently receiving any of the following substances and cannot be discontinued 7 days
prior to study registration:


- Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit
hybrids, pomelos, star-fruit, and Seville oranges.


- Medications that have a narrow therapeutic window and are predominantly
metabolized through CYP3A4/5.


- Known strong inducers or inhibitors of CYP2D6.


- Major surgery within 14 days prior to study registration or has not recovered from
major side effects of surgery.


- Known history of human immunodeficiency virus [(HIV) HIV 1/2 antibodies].


- Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
[qualitative] is detected) (testing not mandatory)


- Any clinically significant infection defined as any acute viral, bacterial, or fungal
infection that requires specific treatment. NOTE: Anti-infective treatment must be
completed ≥ 7 days prior to study registration.


- Known allergy to palbociclib or any of its excipients


- Presence of any non-healing wound, fracture, or ulcer within 28 days prior to study
registration. NOTE: if fracture is at a metastatic site, is chronic, and no surgical
treatment is planned, the subject can be enrolled.


- Any condition that, in the opinion of the investigator, might jeopardize the safety of
the subject or interfere with protocol compliance.


- Any mental or medical condition that prevents the subject from giving informed consent
or participating in the trial.


- Treatment with any therapeutic investigational agent within 28 days prior to
registration for protocol therapy. The subject must have recovered from the acute
toxic effects of the regimen.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast CancerPalbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
NCT02668666
  1. Chicago, Illinois
  2. Lansing, Michigan
  3. Minneapolis, Minnesota
  4. Omaha, Nebraska
  5. Hershey, Pennsylvania
  6. Hershey, Pennsylvania
  7. Madison, Wisconsin
  8. Waukesha, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Official Title  ICMJE A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
Brief Summary This is a non-randomized, open-label, single-arm, multicenter, phase II study of palbociclib in combination with tamoxifen in women with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anticancer therapies for their advanced/metastatic disease.
Detailed Description

OUTLINE: This is a multi-center trial.

INVESTIGATIONAL TREATMENT:

  • Palbociclib 125 mg will be administered orally once daily on days 1-21 (D1-D21) of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
  • Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).

Palbociclib should be taken with food in combination with tamoxifen. Subjects should take their dose at approximately the same time each day.

It is encouraged, but not mandatory, that premenopausal subjects will also receive treatment with goserelin or equivalent (e.g., Lupron) given as an injectable subcutaneous implant on D1 of every 28 days cycle or every 3 months.

Disease assessments will be performed at the completion of every 2 cycles.

Treatment will continue until disease progression, unacceptable toxicity, subject refusal, or subject death either from progression of disease, the therapy itself, or from other causes. Subjects who voluntarily stop the study, have progressive disease, or unacceptable toxicities will be followed for a total of 24 months after discontinuation of study drug.

To demonstrate adequate organ function, all screening labs should be performed within 14 days prior to registration for protocol therapy:

Hematological (must meet ALL of the following criteria):

  • Absolute neutrophil count (ANC) ? 1.5 × 10 9/L
  • Hemoglobin ? 9 g/dL
  • Platelet count ? 100 × 10 9/L

Renal (must meet ONE of the following criteria):

  • Serum creatinine ? 1.5 × ULN
  • Serum creatinine > 1.5 × ULN, estimated glomerular filtration rate (eGFR) ? 40 mL/min

Hepatic (must meet ALL of the following criteria):

  • Aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
  • Alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
  • Total serum bilirubin ? 1.5 × ULN
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description:
Open-Label
Primary Purpose: Treatment
Condition  ICMJE
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Estrogen Receptor Positive Breast Cancer
  • Progesterone Receptor Positive Tumor
  • Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: Palbociclib
    Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
    Other Name: Ibrance
  • Drug: Tamoxifen
    Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
    Other Name: Nolvadex
Study Arms  ICMJE Experimental: Investigational Treatment

71 subjects will be enrolled to determine progression-free survival (PFS) in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies.

Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.

Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).

Interventions:
  • Drug: Palbociclib
  • Drug: Tamoxifen
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 27, 2020)
49
Original Estimated Enrollment  ICMJE
 (submitted: January 27, 2016)
71
Estimated Study Completion Date  ICMJE January 2022
Estimated Primary Completion Date January 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Subjects must meet all of the following applicable inclusion criteria to participate in this study:

  • Male or female ? 18 years of age at time of consent. NOTE: Both pre- and post-menopausal women are eligible. Pre-menopausal status is defined as either:

    • Last menstrual period within the last 12 months.
    • In case of therapy-induced amenorrhea, plasma estradiol and /or FSH is in the premenopausal range per local normal range.
  • Locally advanced, locoregionally recurrent, or metastatic disease, not amenable to curative therapy. NOTE: Although not required as a protocol procedure, a patient with a new metastatic lesion should be considered for biopsy whenever possible to reassess ER/PR/HER2 status if clinically indicated. If a biopsy is prospectively done as part of standard of care, the study would like to store samples for correlative research.
  • Histologically and/or cytologically confirmed diagnosis of ER positive and/or PR positive (ER >1%, PR >1%), HER2 negative breast cancer. NOTE: Subject has HER2-negative breast cancer (based on most recently analyzed biopsy) is defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (e.g. FISH, CISH, SISH, DISH, etc.) test is required by local laboratory testing.
  • Metastatic disease evaluable on imaging studies. Subjects may have measurable disease as per RECIST 1.1 or bone-only disease. NOTE: Bone-only subjects are eligible if their disease can be documented/ evaluated by bone scans, CT or MRI. Their disease will be assessed using MDA criteria. NOTE: Previously irradiated lesions are eligible as a target lesion only if there is documented progression of the lesion after irradiation.
  • No prior systemic anti-cancer therapy for advanced HR+ disease. NOTE: Subjects receiving adjuvant treatment with aromatase inhibitors at time of recurrence are allowed to participate. There is no AI washout period required.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • Provided written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization for release of personal health information, approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC). NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  • Women of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within 72 hours of study registration from women of childbearing potential. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.
  • Women of childbearing potential (WOCP) must be willing to use two effective methods of birth control such as use of a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence for the course of the study until 120 days after the last dose of study drug. The use of hormonal contraceptives is discouraged. NOTE: Women are considered to be of childbearing potential unless they are postmenopausal for at least 12 consecutive months or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  • Male subjects capable of fathering a child must agree to use adequate contraception or total abstinence for the course of the study until 120 days after the last dose of the study drug.

NOTE: Male subjects will be considered as capable of fathering a child unless they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition).

  • Co-enrollment in an imaging biomarker study or other non-therapeutic study is allowed.

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

  • Prior treatment with any CDK 4/6 inhibitor.
  • Confirmed diagnosis of HER2 positive disease.
  • Known uncontrolled or symptomatic CNS metastases. Subjects with known brain metastasis will only be eligible after their tumors have been treated with definitive resection and /or radiotherapy and they are neurologically stable for at least 1 month off steroids.
  • Advanced, symptomatic, visceral spread with a life expectancy less than 4 months.
  • Prior (neo)adjuvant treatment with tamoxifen within the 12 months before study entry.
  • Prior history of blood clots, pulmonary embolism or deep vein thrombosis.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  • Concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated basal cell carcinoma, squamous cell skin carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.
  • Any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate subject participation in the clinical study.
  • Currently receiving any of the following substances and cannot be discontinued 7 days prior to study registration:

    • Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges.
    • Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
    • Known strong inducers or inhibitors of CYP2D6.
  • Major surgery within 14 days prior to study registration or has not recovered from major side effects of surgery.
  • Known history of human immunodeficiency virus [(HIV) HIV 1/2 antibodies].
  • Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) (testing not mandatory)
  • Any clinically significant infection defined as any acute viral, bacterial, or fungal infection that requires specific treatment. NOTE: Anti-infective treatment must be completed ? 7 days prior to study registration.
  • Known allergy to palbociclib or any of its excipients
  • Presence of any non-healing wound, fracture, or ulcer within 28 days prior to study registration. NOTE: if fracture is at a metastatic site, is chronic, and no surgical treatment is planned, the subject can be enrolled.
  • Any condition that, in the opinion of the investigator, might jeopardize the safety of the subject or interfere with protocol compliance.
  • Any mental or medical condition that prevents the subject from giving informed consent or participating in the trial.
  • Treatment with any therapeutic investigational agent within 28 days prior to registration for protocol therapy. The subject must have recovered from the acute toxic effects of the regimen.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02668666
Other Study ID Numbers  ICMJE BTCRC BRE15-016
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party Oana Danciu, MD, Big Ten Cancer Research Consortium
Study Sponsor  ICMJE Oana Danciu, MD
Collaborators  ICMJE
  • Pfizer
  • Big Ten Cancer Research Consortium
Investigators  ICMJE
Study Chair:Oana Danciu, M.D.Big Ten Cancer Research Consortium
PRS Account Big Ten Cancer Research Consortium
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP